INVESTOR RELATIONS

Investors

Welcome to our dedicated page for investor resources. Here you'll find everything you need if you want to invest in pioneering medical science.

Dedicated to solving some of today’s biggest public health challenges, bioMérieux has the focus and the capabilities to discover, develop, and commercialize advanced medical diagnostics solutions that have an impact on people’s lives. We combine the dynamism of a technology-fueled company with the long-term thinking of our founding family. It is this alliance that shapes our strategy and success.

A values-based company, we aim for strong and sustainable performance that benefits our shareholders, our employees, and society.

Investors

First Quarter 2022 Business Review

First-quarter organic growth of -4.5% at constant exchange rates and scope of consolidation:
- €837 million in sales
- Down 0.9% as reported

Solid +6% growth in Industrial Applications and +5% growth in Microbiology

Stable sales of BIOFIRE^® panels, in line with expectations for the quarter

Anticipated headwinds in Immunoassays with lower COVID-related assays demand

2022 Outlook unchanged

“In a continued highly uncertain business environment, our first quarter performance is aligned with our outlook. Sales growth was particularly solid in both microbiology and industrial applications, and in line with our expectations on molecular biology and immunoassays”

Alexandre Mérieux, Chairman and CEO